Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.
作者信息
Paes Bosco, Lanari Marcello, Rodgers-Gray Barry, Fullarton John, Carbonell-Estrany Xavier
机构信息
Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, ON, Canada.
Paediatric Emergency Unit, IRCCS-Policlinico Ospedaliero-Universitario di Bologna, Bologna, Italy.
出版信息
Front Pediatr. 2024 Jan 12;12:1343960. doi: 10.3389/fped.2024.1343960. eCollection 2024.
Abstract
摘要
相似文献
1
Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.
Front Pediatr. 2024 Jan 12;12:1343960. doi: 10.3389/fped.2024.1343960. eCollection 2024.
2
Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
Am J Perinatol. 2022 Dec;39(S 01):S7-S13. doi: 10.1055/s-0042-1757279. Epub 2022 Oct 28.
3
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
J Med Econ. 2023 Jan-Dec;26(1):630-643. doi: 10.1080/13696998.2023.2202600.
4
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990.
5
Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
J Infect Dev Ctries. 2021 Nov 30;15(11):1708-1713. doi: 10.3855/jidc.12561.
6
Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia.
J Allergy Clin Immunol Glob. 2023 Aug 3;2(4):100161. doi: 10.1016/j.jacig.2023.100161. eCollection 2023 Nov.
7
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Pediatrics. 1999 Sep;104(3 Pt 1):419-27. doi: 10.1542/peds.104.3.419.
8
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
PLoS One. 2023 Aug 10;18(8):e0289828. doi: 10.1371/journal.pone.0289828. eCollection 2023.
9
Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands.
Vaccines (Basel). 2023 Dec 2;11(12):1807. doi: 10.3390/vaccines11121807.
10
引用本文的文献
1
Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants.
Pediatr Int. 2025 Jan-Dec;67(1):e70021. doi: 10.1111/ped.70021.
本文引用的文献
1
Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt.
Lancet Reg Health Eur. 2023 Oct 11;34:100753. doi: 10.1016/j.lanepe.2023.100753. eCollection 2023 Nov.
2
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
PLoS One. 2023 Aug 10;18(8):e0289828. doi: 10.1371/journal.pone.0289828. eCollection 2023.
3
Exploring the adoption of less restricted criteria for respiratory syncytial virus prophylaxis in late preterm infants: insights from a retrospective analysis.
Front Pediatr. 2023 Jun 8;11:1154518. doi: 10.3389/fped.2023.1154518. eCollection 2023.
4
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
J Med Econ. 2023 Jan-Dec;26(1):630-643. doi: 10.1080/13696998.2023.2202600.
5
Comparison of the Canadian vs. the international risk scoring tool for respiratory syncytial virus prophylaxis in moderate-to-late preterm infants.
Front Pediatr. 2023 Jan 5;10:997349. doi: 10.3389/fped.2022.997349. eCollection 2022.
6
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
7
Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants.
Curr Med Res Opin. 2021 Jul;37(7):1149-1153. doi: 10.1080/03007995.2021.1911974. Epub 2021 Apr 21.
8
Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies.
Epidemiol Infect. 2020 Aug 17;148:e170. doi: 10.1017/S0950268820001661.
9
Association between respiratory syncytial virus hospitalization in infancy and childhood asthma.
Pediatr Pulmonol. 2020 May;55(5):1104-1110. doi: 10.1002/ppul.24676. Epub 2020 Feb 10.
10
Correction to: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.
Eur J Pediatr. 2020 Feb;179(2):355. doi: 10.1007/s00431-019-03526-1.
Zotero 插件